5
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer - Squamous cell
- Tumour stage
- Metastatic
- Control Arm
- Docetaxel
- Treatment Setting
- 2nd line after platinum-based therapy advanced squamous-cell NSCLC
- Trial Name
- CheckMate 017
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- PFS Control
- 2.8 months
- PFS Gain
- 0.7 months
- PFS HR
- 0.62 (0.47-0.81)
- OS Control
- 6 months
- OS Gain
- 3.2 months 2-year survival gain:15%
- OS HR
- 0.59 (0.44-0.79)
- Toxicity Comment
- Reduced grade 3/4 AE 7% vs 55%
Final Score (after adjustments)
- Preliminary non-curative score
- 4
- Toxicity adjustment
- 1+
- Final non-curative Score
- 5
ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression